The estimated Net Worth of Jane H Hollingsworth is at least $5.72 Тысяча dollars as of 31 May 2023. Jane Hollingsworth owns over 183 units of Diffusion Pharmaceuticals Inc stock worth over $5,716 and over the last 4 years Jane sold DFFN stock worth over $0.
Sign up
Jane Hollingsworth DFFN stock SEC Form 4 insiders trading
Jane has made over 6 trades of the Diffusion Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Jane exercised 183 units of DFFN stock worth $805 on 31 May 2023.
The largest trade Jane's ever made was buying 32,786 units of Diffusion Pharmaceuticals Inc stock on 13 May 2021 worth over $19,999. On average, Jane trades about 4,213 units every 94 days since 2020. As of 31 May 2023 Jane still owns at least 1,299 units of Diffusion Pharmaceuticals Inc stock.
You can see the complete history of Jane Hollingsworth stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jane Hollingsworth's mailing address?
Jane's mailing address filed with the SEC is 300 EAST MAIN ST., SUITE 101, CHARLOTTESVILLE, VA, 22902.
Insiders trading at Diffusion Pharmaceuticals Inc
Over the last 8 years, insiders at Diffusion Pharmaceuticals Inc have traded over $0 worth of Diffusion Pharmaceuticals Inc stock and bought 61,786 units worth $39,139 . The most active insiders traders include Robert Joseph Jr. Cobuzzi, Isaac Blech и Jane H Hollingsworth. On average, Diffusion Pharmaceuticals Inc executives and independent directors trade stock every 60 days with the average trade being worth of $26,721. The most recent stock trade was executed by Diana M Lanchoney on 30 June 2023, trading 232 units of DFFN stock currently worth $1,021.
What does Diffusion Pharmaceuticals Inc do?
diffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. the company is developing its lead drug, trans sodium crocetinate (tsc), which has received orphan drug designation from the fda for use in a number of cancers in which tumor hypoxia (oxygen deprivation) diminishes the efficacy of current treatments. tsc targets the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancerous cells more vulnerable to the therapeutic effects of conventional radiation and chemotherapy. the company is poised to begin a pivotal phase 3 trial in glioblastoma (gbm) in 2016. other programs include planned phase 2/3 trials in pancreatic cancer and brain metastases. because tsc’s novel mechanism safely re-oxygenates a wide range of tumor types, its use is not limited to a specific tumor tissue, but
What does Diffusion Pharmaceuticals Inc's logo look like?
Complete history of Jane Hollingsworth stock trades at Diffusion Pharmaceuticals Inc
Diffusion Pharmaceuticals Inc executives and stock owners
Diffusion Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Dr. Robert J. Cobuzzi Jr.,
Pres, CEO & Director -
William Karl Hornung,
Chief Financial Officer -
Dr. Christopher D. Galloway M.D.,
Chief Medical Officer -
William Robert Elder J.D.,
Gen. Counsel & Corp. Sec. -
Dr. Jennifer Llewelyn Ph.D.,
Sr. Director & Head of CMC -
Suzanne Cassidy,
Sr. Director & Head of Quality Assurance -
Brian D. Bollwage,
Sr. Consultant - Regulatory Affairs -
Douglas Gravatt,
Sr. Consultant for Manufacturing -
Harry Cook,
VP of Clinical Operations -
Kelly Hoy,
Director of Project Management -
Dr. David Randolph Jones M.D.,
Sr. Medical Advisor -
William Karl Hornung,
Chief Financial Officer -
Mark T Giles,
Director -
John Gainer,
Chief Scientific Officer -
Robert R Ruffolo,
Director -
David G Kalergis,
Chairman and CEO -
Robert W Adams,
Director -
Thomas E Byrne,
General Counsel -
Alan G Levin,
Director -
Isaac Blech,
Director -
Ben Shealy,
Senior Vice President Finance -
Jane H Hollingsworth,
Director -
Robert Joseph Jr. Cobuzzi,
President & CEO -
Eric Francois,
Director -
William Robert Elder,
GC & Secretary -
Christopher D Galloway,
Chief Medical Officer -
Diana M Lanchoney,
Director -
Raven Jaeger,
Chief Regulatory Officer